内容紹介
Summary
The study subjects consisted of 54 patients with inoperable or recurrent breast cancer who were administered a combination of palbociclib plus endocrine therapy. We examined the onset of neutropenia during the first course of treatment and evaluated the influence that various risk factors had on treatment continuity. Patients with neutropenia Grade≥3 had significantly lower relative dose intensity(RDI) values during the first course of treatment than did patients with neutropenia Grade≤2. Patients with neutropenia Grade≥3 showed significantly longer treatment to failure than did patients with neutropenia Grade≤2. These results suggest that the degree of neutropenia during the first course of treatment might contribute to treatment continuity and that it is important to improve the curative effect by maintaining appropriate RDI and by continuously administering palbociclib in patients with neutropenia Grade≥3.
要旨
手術不能または再発乳がんに対してパルボシクリブ+内分泌療法剤併用療法が開始された54例を対象とし,1コース目におけるGrade 3以上の重篤な好中球減少の発現状況を調査し,様々なリスク因子が治療継続性へ及ぼす影響を検討した。その結果,Grade 3以上好中球減少群は,Grade 2以下好中球減少群と比較して1コース目における相対用量強度(RDI)が有意に低かった。また,Grade 3以上好中球減少群の治療成功期間は,Grade 2以下好中球減少群よりも有意に長かった。1コース目での好中球減少の重症度が治療継続性に寄与する可能性があること,またGrade 3以上の好中球減少が発現した場合においても適切なRDIを維持し,パルボシクリブを継続投与することが治療効果向上に重要であることが示唆された。
目次
The study subjects consisted of 54 patients with inoperable or recurrent breast cancer who were administered a combination of palbociclib plus endocrine therapy. We examined the onset of neutropenia during the first course of treatment and evaluated the influence that various risk factors had on treatment continuity. Patients with neutropenia Grade≥3 had significantly lower relative dose intensity(RDI) values during the first course of treatment than did patients with neutropenia Grade≤2. Patients with neutropenia Grade≥3 showed significantly longer treatment to failure than did patients with neutropenia Grade≤2. These results suggest that the degree of neutropenia during the first course of treatment might contribute to treatment continuity and that it is important to improve the curative effect by maintaining appropriate RDI and by continuously administering palbociclib in patients with neutropenia Grade≥3.
要旨
手術不能または再発乳がんに対してパルボシクリブ+内分泌療法剤併用療法が開始された54例を対象とし,1コース目におけるGrade 3以上の重篤な好中球減少の発現状況を調査し,様々なリスク因子が治療継続性へ及ぼす影響を検討した。その結果,Grade 3以上好中球減少群は,Grade 2以下好中球減少群と比較して1コース目における相対用量強度(RDI)が有意に低かった。また,Grade 3以上好中球減少群の治療成功期間は,Grade 2以下好中球減少群よりも有意に長かった。1コース目での好中球減少の重症度が治療継続性に寄与する可能性があること,またGrade 3以上の好中球減少が発現した場合においても適切なRDIを維持し,パルボシクリブを継続投与することが治療効果向上に重要であることが示唆された。